The impact of mid-treatment MRI on defining boost volumes in the radiation treatment of glioblastoma multiforme

Rafael Manon, Susanta Hui, Prakash Chinnaiyan, John Suh, Eric Chang, Robert Timmerman, See Phan, Rupak Das, Minesh Mehta

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Radiation therapy is a central modality in the treatment of glioblastoma multiforme (GBM). Integral to adequate radiation therapy delivery is the appropriate determination of tumor volume and extent at the time treatment is being delivered. As a matter of routine practice, radiation therapy treatment fields are designed based on tumor volumes evident on pre-operative or immediate post-operative MRIs; another MRI is generally not obtained for planning boost fields. In some instances the time interval from surgery to radiotherapy initiation is up to 5 weeks and the boost or "cone-down phase" commences 4-5 weeks later. The contrast enhanced T1 MRI may not be a totally reliable indicator of active tumor, especially in regions where such blood-brain barrier breakdown has not occurred. Moreover, these volumes may change during the course of treatment. This may lead to a geographic miss when mid-treatment boost volumes are designed based on a pre-radiotherapy MRI. The goal of this study is to examine how a mid-treatment MRI impacts the delineation and definition of the boost volume in GBM patients in comparison to the pre-treatment MRI scan, particularly when the tumor-specific agent Motexafin-Gadolinium is used.

Original languageEnglish (US)
Pages (from-to)303-307
Number of pages5
JournalTechnology in Cancer Research and Treatment
Volume3
Issue number3
StatePublished - Jun 2004

Fingerprint

Glioblastoma
Radiation
Radiotherapy
Tumor Burden
Therapeutics
Blood-Brain Barrier
Neoplasms
Magnetic Resonance Imaging

Keywords

  • Glioblastoma treatment planning
  • Motexafin gadolinium
  • Target volumes

ASJC Scopus subject areas

  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

The impact of mid-treatment MRI on defining boost volumes in the radiation treatment of glioblastoma multiforme. / Manon, Rafael; Hui, Susanta; Chinnaiyan, Prakash; Suh, John; Chang, Eric; Timmerman, Robert; Phan, See; Das, Rupak; Mehta, Minesh.

In: Technology in Cancer Research and Treatment, Vol. 3, No. 3, 06.2004, p. 303-307.

Research output: Contribution to journalArticle

Manon, R, Hui, S, Chinnaiyan, P, Suh, J, Chang, E, Timmerman, R, Phan, S, Das, R & Mehta, M 2004, 'The impact of mid-treatment MRI on defining boost volumes in the radiation treatment of glioblastoma multiforme', Technology in Cancer Research and Treatment, vol. 3, no. 3, pp. 303-307.
Manon, Rafael ; Hui, Susanta ; Chinnaiyan, Prakash ; Suh, John ; Chang, Eric ; Timmerman, Robert ; Phan, See ; Das, Rupak ; Mehta, Minesh. / The impact of mid-treatment MRI on defining boost volumes in the radiation treatment of glioblastoma multiforme. In: Technology in Cancer Research and Treatment. 2004 ; Vol. 3, No. 3. pp. 303-307.
@article{e4d1bc31eaf944b69a123e30f6feac15,
title = "The impact of mid-treatment MRI on defining boost volumes in the radiation treatment of glioblastoma multiforme",
abstract = "Radiation therapy is a central modality in the treatment of glioblastoma multiforme (GBM). Integral to adequate radiation therapy delivery is the appropriate determination of tumor volume and extent at the time treatment is being delivered. As a matter of routine practice, radiation therapy treatment fields are designed based on tumor volumes evident on pre-operative or immediate post-operative MRIs; another MRI is generally not obtained for planning boost fields. In some instances the time interval from surgery to radiotherapy initiation is up to 5 weeks and the boost or {"}cone-down phase{"} commences 4-5 weeks later. The contrast enhanced T1 MRI may not be a totally reliable indicator of active tumor, especially in regions where such blood-brain barrier breakdown has not occurred. Moreover, these volumes may change during the course of treatment. This may lead to a geographic miss when mid-treatment boost volumes are designed based on a pre-radiotherapy MRI. The goal of this study is to examine how a mid-treatment MRI impacts the delineation and definition of the boost volume in GBM patients in comparison to the pre-treatment MRI scan, particularly when the tumor-specific agent Motexafin-Gadolinium is used.",
keywords = "Glioblastoma treatment planning, Motexafin gadolinium, Target volumes",
author = "Rafael Manon and Susanta Hui and Prakash Chinnaiyan and John Suh and Eric Chang and Robert Timmerman and See Phan and Rupak Das and Minesh Mehta",
year = "2004",
month = "6",
language = "English (US)",
volume = "3",
pages = "303--307",
journal = "Technology in Cancer Research and Treatment",
issn = "1533-0346",
publisher = "Adenine Press",
number = "3",

}

TY - JOUR

T1 - The impact of mid-treatment MRI on defining boost volumes in the radiation treatment of glioblastoma multiforme

AU - Manon, Rafael

AU - Hui, Susanta

AU - Chinnaiyan, Prakash

AU - Suh, John

AU - Chang, Eric

AU - Timmerman, Robert

AU - Phan, See

AU - Das, Rupak

AU - Mehta, Minesh

PY - 2004/6

Y1 - 2004/6

N2 - Radiation therapy is a central modality in the treatment of glioblastoma multiforme (GBM). Integral to adequate radiation therapy delivery is the appropriate determination of tumor volume and extent at the time treatment is being delivered. As a matter of routine practice, radiation therapy treatment fields are designed based on tumor volumes evident on pre-operative or immediate post-operative MRIs; another MRI is generally not obtained for planning boost fields. In some instances the time interval from surgery to radiotherapy initiation is up to 5 weeks and the boost or "cone-down phase" commences 4-5 weeks later. The contrast enhanced T1 MRI may not be a totally reliable indicator of active tumor, especially in regions where such blood-brain barrier breakdown has not occurred. Moreover, these volumes may change during the course of treatment. This may lead to a geographic miss when mid-treatment boost volumes are designed based on a pre-radiotherapy MRI. The goal of this study is to examine how a mid-treatment MRI impacts the delineation and definition of the boost volume in GBM patients in comparison to the pre-treatment MRI scan, particularly when the tumor-specific agent Motexafin-Gadolinium is used.

AB - Radiation therapy is a central modality in the treatment of glioblastoma multiforme (GBM). Integral to adequate radiation therapy delivery is the appropriate determination of tumor volume and extent at the time treatment is being delivered. As a matter of routine practice, radiation therapy treatment fields are designed based on tumor volumes evident on pre-operative or immediate post-operative MRIs; another MRI is generally not obtained for planning boost fields. In some instances the time interval from surgery to radiotherapy initiation is up to 5 weeks and the boost or "cone-down phase" commences 4-5 weeks later. The contrast enhanced T1 MRI may not be a totally reliable indicator of active tumor, especially in regions where such blood-brain barrier breakdown has not occurred. Moreover, these volumes may change during the course of treatment. This may lead to a geographic miss when mid-treatment boost volumes are designed based on a pre-radiotherapy MRI. The goal of this study is to examine how a mid-treatment MRI impacts the delineation and definition of the boost volume in GBM patients in comparison to the pre-treatment MRI scan, particularly when the tumor-specific agent Motexafin-Gadolinium is used.

KW - Glioblastoma treatment planning

KW - Motexafin gadolinium

KW - Target volumes

UR - http://www.scopus.com/inward/record.url?scp=2942666236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942666236&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 303

EP - 307

JO - Technology in Cancer Research and Treatment

JF - Technology in Cancer Research and Treatment

SN - 1533-0346

IS - 3

ER -